Recent Articles

Lung Cancer

PDF FullText DOI: 10.52338/tclc.2024.1005

Lung Cancer Risk factors - A Review Article

PDF FullText DOI: 10.52338/tclc.2024.1004

A randomized placebo-controlled clinical study of nab-paclitaxel as second-line chemotherapy for patients with advanced non-small cell lung cancer in China.

PDF FullText DOI: 10.52338/tclc.2024.1003

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous nonsmall-cell lung cancer: Survival follow-up results of the randomized JO25567 study.

PDF FullText DOI: 10.52338/tclc.2024.1002

Lung cancer prediction by Deep Learning to identify benign lung nodules.

PDF FullText DOI: 10.52338/tclc.2024.1001

Journal Info

  • Journal Name: The Clinical Lung Cancer
  • Impact Factor: 1.8
  • ISSN: 3064-6693
  • DOI: 10.52338/tclc
  • Short Name: Tclc
  • Acceptance rate: 55%
  • Volume: 7 (2024)
  • Submission to acceptance: 25 days
  • Acceptance to publication: 10 days
  • Crossref indexed journal
  • Publons indexed journal
  • Pubmed-indexed journal
  • International Scientific Indexing (ISI)-indexed journal
  • Eurasian Scientific Journal Index (ESJI) index journal
  • Semantic Scholar indexed journal
  • Cosmos indexed journal

OUR PUBLICATION BENEFITS

  • International Reach
  • Peer Review
  • Rapid Publication
  • Open Access
  • High Visibility